Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525029 · ClinicalTrials.gov registry record · Phase 1
Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT02525029 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 53 participants.
The verdict
NCT02525029, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of Pregnyl® when given in combination with standard immunosuppressive therapy in pediatric and adult patients with high-risk (Arm 1) or refractory/dependent (Arm 2) aGVHD.
Interventions
- DRUG Pregnyl®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2016-03 |
| Est. Completion | 2022-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02525029
The ClinicalTrials.gov registry entry for NCT02525029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pregnyl® is the first listed.
NCT02525029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02525029 about?
NCT02525029 is a clinical study titled "Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD". The purpose of this study is to determine the maximum tolerated dose (MTD) of Pregnyl® when given in combination with standard immunosuppressive therapy in pediatric and adult patients with high-risk (Arm 1) or refractory/dependent (Arm 2) aGVHD.
What is the current status of trial NCT02525029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2016-03. Estimated completion is 2022-04.
What interventions are being tested in trial NCT02525029?
The interventions under investigation include: Pregnyl® (DRUG).
Who is sponsoring clinical trial NCT02525029?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.